Comprehensive Parkinson's Disease CRO Solutions for Drug Discovery
Overcome the challenges of Parkinson's drug discovery with Cyagen. Our integrated platform offers validated animal models and expert CRO services, providing reliable and efficient research support to scientists developing novel PD therapeutics.
An Integrated Approach to PD Research & Its Challenges
As the second most common neurodegenerative disorder, Parkinson's Disease has a significant global impact with substantial unmet medical needs. Key research bottlenecks include the need for models that accurately recapitulate the key features of synucleinopathy and the complexity of evaluating motor and non-motor symptoms.
To address these challenges, Cyagen has developed a powerful and integrated research platform. Our
portfolio of specialized synucleinopathy models, combined with comprehensive in vivo and in vitro
services detailed below, provides the critical tools scientists need to overcome these hurdles and
accelerate their PD discovery programs.
{{ item.title }}
{{static_tabs[0].title}}
Our comprehensive portfolio of Parkinson's Disease (PD) models is centered on synucleinopathy,
the key pathological hallmark of the disease. The table below includes both our validated,
ready-to-use models for immediate deployment, and our advanced R&D platform for key pathogenic
mutations, available for custom projects and collaborative research.
| Target Class | Model Name | Key Features | Status | Details |
|---|---|---|---|---|
| Synucleinopathy | B6-hSNCA | Humanized SNCA (Wild-Type) | Ready-to-Use | View |
| B6-hSNCA (3'UTR) | Humanized SNCA (with 3'UTR) | Ready-to-Use | View | |
| hSNCA (A53T) | Humanized SNCA (A53T Mutation) | R&D | - |
Can't find the model you need?
Explore hundreds of additional off-the-shelf neuroscience models in our MouseAtlas database, or partner with
our scientific team to develop a custom-engineered model tailored to your exact research
specifications.
{{static_tabs[1].title}}
Precision Drug Administration
Our team is highly experienced in the precision dosing and administration
methods critical for PD research, including routes that target the central nervous system.
- Systemic Delivery: Intravenous (tail vein), Intraperitoneal, Subcutaneous, etc.
- CNS-Targeted Delivery: Stereotactic brain injection into key regions like the substantia nigra or striatum.
Neurobehavioral Assessment for PD
We provide a battery of behavioral paradigms essential for evaluating the core motor and
non-motor deficits associated with Parkinson's Disease.
| Behavioral Domain | Recommended Tests for PD Research | Function Tested |
|---|---|---|
| Motor Function & Coordination | Rotarod Test | Motor coordination, balance, ataxia |
| Pole Test | Bradykinesia, motor coordination | |
| Grip Strength | Muscle strength | |
| Gait Analysis | Fine motor coordination and balance | |
| Cognitive & Psychiatric | Open Field Test | Spontaneous locomotor activity-related behavior |
{{static_tabs[2].title}}
We offer a focused suite of analytical services to investigate the core
pathological and molecular features of Parkinson's Disease, and to evaluate the efficacy of
your therapeutic candidates.
| Analysis Category | Specific Services | Key Applications & Targets in PD Research |
|---|---|---|
| Pathology & Biomarker Analysis | Histology & IHC/IF | Visualize and quantify key pathological hallmarks, including α-synuclein aggregates (pS129, total) and assess dopaminergic neuron health and loss via Tyrosine Hydroxylase (TH) staining. |
| ELISA & Immunoassays | Accurately quantify levels of total and aggregated α-synuclein in brain tissue and other biological samples. | |
| Neurotransmitter Analysis (HPLC) | Measure the levels of dopamine and its key metabolites (DOPAC, HVA) in the striatum and other relevant brain regions to assess the integrity of the nigrostriatal pathway. | |
| Gene & Protein Expression | Western Blot | Assess changes in α-synuclein (SNCA) protein levels, post-translational modifications (e.g., phosphorylation), and aggregation status. |
| RT-PCR & qPCR | Analyze the expression of the SNCA gene and other relevant therapeutic or pathological target genes to understand mechanistic changes. |
Case Studies
Our models undergo rigorous validation to ensure they are robust and reliable tools for your research.
Explore our case studies below, which highlight the successful characterization of our humanized genetic
models and our expertise in conducting preclinical drug efficacy studies.
Case Study 1: B6-hSNCA (3'UTR): Validating Human SNCA Expression
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Case Study 2: B6-hSNCA: Confirming Orthologous Gene Replacement
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Case Study 3: Drug Efficacy Study in a 6-OHDA Induced PD Model
Validating Drug Efficacy in a Neurotoxin-Induced PD Model
| Model Construction | Treatments & Behavioral Assessments |
|---|---|
| A 6-OHDA solution was injected into the left brain medial forebrain bundle and substantia nigra. Two weeks later, apomorphine was administered intraperitoneally to the rats, and rightward rotations were counted. | Levodopa (L-DOPA) was injected intraperitoneally daily. At specified time points, gait analysis, grip strength, and rotarod performance were measured. |
Model Induction and Study Design. A classic PD model was induced via stereotaxic injection of
the neurotoxin 6-OHDA into the medial forebrain bundle and substantia nigra of rats. After a 2-week
validation period, the gold-standard drug Levodopa (L-DOPA) was administered daily to assess the
model's utility for pharmacological studies.
Figure 5. Reversal of Motor Deficits with L-DOPA Treatment. The 6-OHDA lesion was first
confirmed by apomorphine (APO)-induced rotations, a hallmark of unilateral dopamine depletion.
Subsequent behavioral testing revealed that PD rats had significant impairments in gait, grip
strength, and rotarod performance compared to WT controls. Daily administration of L-DOPA
successfully reversed these motor deficits, demonstrating the model's robust and reliable response
to therapeutic intervention.
Why Partner with Cyagen?
Comprehensive Model Solutions
Gain access to validated humanized SNCA models and leverage our expertise in developing custom models for other PD-related targets.
Integrated Efficacy Platform
Utilize our one-stop services—from motor function assessment to terminal neurochemical and pathological analysis.
Data-Driven Decision Support
Our stringent quality control and commitment to reproducibility deliver reliable data for your project decisions.
Expert-Led Study Design
Collaborate with our senior scientists for end-to-end support, from model selection to customized protocol design.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.